PhagenCorp has developed a novel therapeutic treatment option based on new technology that can facilitate the elimination of infection more rapidly and efficiently than conventional treatments, all without harming the body’s existing infrastructure. We recently conducted a study demonstrating the never-before-seen effects of this treatment option, known as Induced Native Phage Therapy.
INPT is a patent-pending technology that uses a proprietary adjunctive assay called Biospectral Emission Sequencing to identify and isolate specific electromagnetic signatures in order to induce native phages, or those that have entered the body alongside the microbes of a patient’s initial infection, to epigenetically revert from lysogenic to virulent activity. This purposeful manipulation of the body’s natural defense mechanisms causes those microbe-specific phages to kill off their host bacteria entirely, safely ridding the patient of infection in very little time.
A total of 26 patients suffering from post-treatment (antibiotic) Lyme disease syndrome were submitted to INPT treatments over the course of two weeks. 77% of patients were found to be negative after two weeks of treatment. 92% of patients were found to be negative for one or more of their previously diagnosed Borrelia strains following extended INPT treatment. All patients demonstrated no adverse reactions and noted mild to substantial symptom improvement following treatment. To review the study in detail, please click here (Article: Induced Native Phage Therapy for the Treatment of Lyme Disease and Relapsing Fever: A Retrospective Review of First 14 Months in One Clinic).